SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:liu-163656"
 

Sökning: id:"swepub:oai:DiVA.org:liu-163656" > The novel ghrelin r...

The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study

Lee, Mary R. (författare)
NIAAA, MD 20892 USA; NIDA, MD 20892 USA
Tapocik, Jenica D. (författare)
NIDA, MD 20892 USA
Ghareeb, Mwlod (författare)
Univ Rhode Isl, RI 02881 USA
visa fler...
Schwandt, Melanie L. (författare)
NIAAA, MD USA
Dias, Alexandra A. (författare)
NIAAA, MD 20892 USA; NIDA, MD 20892 USA
Le, April N. (författare)
NIAAA, MD 20892 USA; NIDA, MD 20892 USA
Cobbina, Enoch (författare)
Univ Rhode Isl, RI 02881 USA
Farinelli, Lisa A. (författare)
NIAAA, MD 20892 USA; NIDA, MD 20892 USA
Bouhlal, Sofia (författare)
NIAAA, MD 20892 USA; NIDA, MD 20892 USA
Farokhnia, Mehdi (författare)
NIAAA, MD 20892 USA; NIDA, MD 20892 USA
Heilig, Markus (författare)
Section on Molecular Pathophysiology, Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, USA
Akhlaghi, Fatemeh (författare)
Univ Rhode Isl, RI 02881 USA
Leggio, Lorenzo (författare)
NIAAA, MD 20892 USA; NIDA, MD 20892 USA; Brown Univ, RI 02912 USA
visa färre...
 (creator_code:org_t)
2018-05-04
2020
Engelska.
Ingår i: Molecular Psychiatry. - : NATURE PUBLISHING GROUP. - 1359-4184 .- 1476-5578. ; 25:2, s. 461-475
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Rodent studies indicate that ghrelin receptor blockade reduces alcohol consumption. However, no ghrelin receptor blockers have been administered to heavy alcohol drinking individuals. Therefore, we evaluated the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and behavioral effects of a novel ghrelin receptor inverse agonist, PF-5190457, when co-administered with alcohol. We tested the effects of PF-5190457 combined with alcohol on locomotor activity, loss-of-righting reflex (a measure of alcohol sedative actions), and on blood PF-5190457 concentrations in rats. Then, we performed a single-blind, placebo-controlled, within-subject human study with PF-5190457 (placebo/0 mg b.i.d., 50 mg b.i.d., 100 mg b.i.d.). Twelve heavy drinkers during three identical visits completed an alcohol administration session, subjective assessments, and an alcohol cue-reactivity procedure, and gave blood samples for PK/PD testing. In rats, PF-5190457 did not interact with the effects of alcohol on locomotor activity or loss-of-righting reflex. Alcohol did not affect blood PF-5190457 concentrations. In humans, all adverse events were mild or moderate and did not require discontinuation or dose reductions. Drug dose did not alter alcohol concentration or elimination, alcohol-induced stimulation or sedation, or mood during alcohol administration. Potential PD markers of PF-5190457 were acyl-to-total ghrelin ratio and insulin-like growth factor-1. PF-5190457 (100 mg b.i.d.) reduced alcohol craving during the cue-reactivity procedure. This study provides the first translational evidence of safety and tolerability of the ghrelin receptor inverse agonist PF-5190457 when co-administered with alcohol. PK/PD/behavioral findings support continued research of PF-5190457 as a potential pharmacological agent to treat alcohol use disorder.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy